Drugs / ChAdOx1 biEBOV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05301504 | Mar 2022 → Dec 2023 | Ebola hemorrhagic fever | University of Oxford | Unknown | No outcome recorded |
| Phase 1 | NCT05079750 | Nov 2021 → Mar 2023 | Ebola hemorrhagic fever | University of Oxford | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1 biEBOV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05079750 ↗ |
| Modality | Vaccine | “a bivalent ChAdOx1 vectored vaccine” NCT05079750 ↗ |
| Route | Intramuscular | “The vaccine will be administered intramuscularly (IM).” NCT05079750 ↗ |